Joseph S. Mccracken net worth and biography

Joseph Mccracken Biography and Net Worth

Director of Savara

Dr. McCracken has served as Savara’s lead independent director since December 2019 and as a member of the company’s Board of Directors since October 2013. Dr. McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives. He also serves on the Board of Directors of Modalis Therapeutics Corporation, as well as the Board of Directors of the privately held company Eos Therapies. Dr. McCracken previously served on the Board of Directors of Lumos Pharma, Inc., Kindred Biosciences, Inc., and Alkahest, Inc. until their acquisitions in 2024, 2021, and 2020, respectively. He also served on the Board of Directors for Neuropore Therapies until February of 2024 and Regimmune Inc. until May of 2023. Previously, Dr. McCracken was Vice President and Global Head of Business Development and Licensing for Roche Pharma, a research-focused healthcare company, where he was responsible for global in-licensing and out-licensing activities. Prior to that he served as General Manager, Roche Pharma Japan and Asia Regional Head, Roche Partnering. Prior to Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a B.S. in Microbiology, a M.S. in Pharmacology, and a D.V.M. from The Ohio State University.

What is Joseph S. Mccracken's net worth?: The estimated net worth of Joseph S. Mccracken is at least $623.40 thousand as of May 29th, 2025. Mccracken owns 260,837 shares of Savara stock worth more than $623,400 as of July 12th. This net worth estimate does not reflect any other assets that Mccracken may own. Learn More about Joseph S. Mccracken's net worth.
How do I contact Joseph S. Mccracken?: The corporate mailing address for Mccracken and other Savara executives is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. Savara can also be reached via phone at 512-614-1848 and via email at [email protected]. Learn More on Joseph S. Mccracken's contact information.
Has Joseph S. Mccracken been buying or selling shares of Savara?: Joseph S. Mccracken has not been actively trading shares of Savara during the last ninety days. Most recently, on Thursday, May 29th, Joseph S. Mccracken bought 10,000 shares of Savara stock. The stock was acquired at an average cost of $2.08 per share, with a total value of $20,800.00. Following the completion of the transaction, the director now directly owns 260,837 shares of the company's stock, valued at $542,540.96. Learn More on Joseph S. Mccracken's trading history.
Who are Savara's active insiders?: Savara's insider roster includes Badrul Chowdhury (Insider), Nevan Elam (Director), Richard Hawkins (Director), David Lowrance (CFO), Joseph Mccracken (Director), Matthew Pauls (CEO), Raymond Pratt (Insider), and David Ramsay (Director). Learn More on Savara's active insiders.
Are insiders buying or selling shares of Savara?: In the last twelve months, Savara insiders bought shares 3 times. They purchased a total of 78,225 shares worth more than $178,179.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 54,702 shares worth more than $181,063.62. The most recent insider tranaction occured on June, 20th when Director Richard J Hawkins bought 48,225 shares worth more than $98,379.00. Insiders at Savara own 5.3% of the company. Learn More about insider trades at Savara.
Information on this page was last updated on 6/20/2025.

Joseph S. Mccracken Insider Trading History at Savara

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/29/2025	Buy	10,000	$2.08	$20,800.00	260,837
11/19/2024	Buy	20,000	$2.95	$59,000.00	210,837
3/15/2021	Buy	68,965	$1.45	$99,999.25	168,337
6/7/2017	Buy	52,250	$4.75	$248,187.50	59,866

Joseph S. Mccracken Buying and Selling Activity at Savara

Savara Company Overview

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Today's Range

Now: $2.39

$2.24

$2.43

50 Day Range

MA: $2.49

$1.94

$3.28

2 Week Range

Now: $2.39

$1.89

$5.11

Volume

1,084,233 shs

Average Volume

1,273,335 shs

Market Capitalization

$413.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31